

[Methylprednisolone](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.4. Hormones and antihormones](#)

ATC codes: [H02AB04](#)

EMLc

Indication

Lymphoid leukaemia, not elsewhere classified ICD11 code: [2B33.3](#)

INN

Methylprednisolone

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection (EMLc) ; 125 mg in vial (as sodium succinate) powder for injection (EMLc)

EML status history

First added in 2011 ([TRS 965](#))

Changed in 2015 ([TRS 994](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Children (1 month - 12 years)

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Methylprednisolone](#)

DrugBank

[Methylprednisolone](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of methylprednisolone 125 mg powder for injection to the EMLc; - the deletion of methylprednisolone injection 80 mg/mL from the EMLc; - update the description of methylprednisolone 40 mg injection (powder for injection in vial).